Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma-Reference-Cited by-同舟云学术

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Published:2020-10-12 Issue:12 Volume:26 Page:1845-1851
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Gao Jianjun^ORCID,Navai Neema,Alhalabi Omar^ORCID,Siefker-Radtke Arlene,Campbell Matthew T.^ORCID,Tidwell Rebecca Slack^ORCID,Guo Charles C.,Kamat Ashish M.,Matin Surena F.,Araujo John C.,Shah Amishi Y.,Msaouel Pavlos,Corn Paul,Wang Jianbo,Papadopoulos John N.,Yadav Shalini S.,Blando Jorge M.,Duan Fei,Basu Sreyashi^ORCID,Liu Wenbin,Shen Yu^ORCID,Zhang Yuwei,Macaluso Marc Daniel,Wang Ying,Chen Jianfeng,Zhang Jianhua^ORCID,Futreal Andrew^ORCID,Dinney Colin,Allison James P.,Goswami Sangeeta,Sharma Padmanee^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-020-1086-y.pdf

Reference54 articles.

1. Necchi, A. et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J. Clin. Oncol. 36, 3353–3360 (2018).

2. Powles, T. et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med. 25, 1706–1714 (2019).

3. Culp, S. H. et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J. Urol. 191, 40–47 (2014).

4. Siefker-Radtke, A. O. et al. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer 119, 540–547 (2013).

5. Moschini, M. et al. Validation of preoperative risk grouping of the selection of patients most likely to benefit from neoadjuvant chemotherapy before radical cystectomy. Clin. Genitourin. Cancer 15, e267–e273 (2017).

Cited by 183 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive breast cancer revealed by single-cell RNA sequencing;Cancer Letters;2024-03

2. Immune infiltration related CENPI associates with the malignant features and drug resistance of lung adenocarcinoma;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-03

3. Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures;Aging;2024-02-01

4. Predictors of response to neoadjuvant therapy in urothelial cancer;Critical Reviews in Oncology/Hematology;2024-02

5. The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?;European Journal of Cancer;2024-02